Unique Plan Description: alvimopan (Entereg)
Plan Selection Display: alvimopan (Entereg)
PlanType: Medical                                 
Version: 1          
Begin Effective Date: 2021-03-11 07:01:00
End Effective Date: 2100-12-31 00:00:00
Last Updated Date: 2021-12-21 12:36:39
Available at all facilities: Yes

alvimopan (Entereg)
Admit/Discharge/Transfer
		This Risk Evaluation and Mitigation Strategy (REMS) is a strategy to mitigate the potential risk ofMI associated with long-term use of alvimopan.(NOTE)*
		REMS requirements: select link for web page(NOTE)*
		REMS Program Overview(NOTE)*
		REMS Dear Healthcare Provider Letter(NOTE)*
		REMS Prescriber and Pharmacist Information(NOTE)*
		Prescribing Information(NOTE)*
		Alvimopan REMS Hospital Pharmacy Enrollment Form(NOTE)*
Medications
	alvimopan
		12 mg, Capsule, By Mouth, BID, duration: 14 Dose(s)/Time(s)
		<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><HTML><HEAD><META content="text/html; charset=windows-1252" http-equiv=Content-Type><STYLE> BODY margin:0; P margin:0 </STYLE><META name=GENERATOR content="MSHTML 11.00.9600.19940(NOTE)*

*Report Legend:
DEF - This order sentence is the default for the selected order
GOAL - This component is a goal
IND - This component is an indicator
INT - This component is an intervention
IVS - This component is an IV Set
NOTE - This component is a note
Rx - This component is a prescription
SUB - This component is a sub phase